#USA #California #Ascletis #Obesity Treatment #ASC30

Promising Results for ASC30 in Obesity Treatment

Ascletis Pharma Inc. has announced the positive results of a Phase II clinical trial for its innovative obesity treatment, ASC30, a subcutaneous depot formulation of a small molecule GLP-1 receptor agonist.

In this 24-week study conducted in the United States, participants using ASC30 experienced a remarkable average weight loss of 7.5% at week 16, significantly outperforming those who received a placebo. 65 individuals who were either obese or overweight, all with at least one weight-related condition, were involved in the study, receiving three monthly doses of the ASC30 formulation.

Study Overview

The study was designed as a randomized, double-blind, placebo-controlled trial, spread across multiple centers. The primary endpoint was met by the ASC30 formulation A1, confirming its effectiveness in inducing weight loss. Participants administered this formulation exhibited a statistically significant average weight loss of 6.3% and later 7.5% at specified weeks.

The structure of the trial allowed for three injections at intervals of a month, avoiding the need for lead-in weekly doses common in other treatments. Following the final dose, participants continued to show maintained weight loss during a 16-week observation period.

A New Approach to Obesity Management

The significance of this study lies not only in weight loss marks but also in the potential dosage convenience. ASC30 opens the door for patients to receive treatment through simple once-monthly or even quarterly injections. This feature could simplify obesity management routines for patients and physicians alike, reducing the burden of frequent treatments.

Interestingly, the safety profile of ASC30 was comparable to existing GLP-1 medications, with no severe side effects reported during the trial. All adverse events recorded, including gastrointestinal issues, were generally mild. This finding provides assurance for healthcare providers considering prescribing ASC30.

Comments from Leadership

Dr. Jinzi Jason Wu, Founder, Chairman and CEO of Ascletis, expressed excitement regarding these findings, emphasizing the competitive efficacy and well-tolerated safety profile of ASC30. He stated, “This competitive efficacy combined with a well-tolerated safety profile of the long-acting formulation reinforces our confidence in expanding our clinical development program.”

Future Implications

The study's data validate the Ultra-Long-Acting Platform (ULAP) technology of Ascletis, which emphasizes the company’s commitment to developing effective therapies for chronic weight management. Additionally, ASC30 stands as a pioneering solution in the GLP-1 drug class, marking itself as the first formulation to propose the possibility of quarterly dosing without introducing weekly lead-ins.

About ASC30

ASC30 is not merely a new entry into the market but is positioned as a unique and versatile medication, being the first and only investigational small molecule GLP-1 receptor biased agonist that can be administered both orally and through subcutaneous injection. With patent protection extending until 2044, this innovation bodes well for future developments in obesity treatments.

Conclusion

Ascletis Pharma has marked a notable advancement with ASC30, reflecting potential shifts in how obesity is treated holistically. With drug safety, efficacy, and convenience becoming priority factors, the future outlook for ASC30 appears promising. As ongoing research continues to unfold, the hope for effective management of obesity disorders may soon be more attainable for patients worldwide.